Insulin sensitizing agents, such as the thiazolidinediones pioglitazone and rosiglitazone, have been used in clinical trials for the treatment of nonalcoholic steatohepatitis, a common form of liver disease that is associated with insulin resistance. The results of these trials have been variable, suggesting that a deeper understanding of other contributing factors to the development of nonalcoholic steatohepatitis is needed to establish whether improving adipose insulin sensitivity might be important.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Clark, J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40, S5–S10 (2006).
Ratziu, V. et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51, 445–453 (2010).
Ratziu, V. et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135, 100–110 (2008).
Gastaldelli, A. et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50, 1087–1093 (2009).
Sanyal, A. J. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183–1192 (2001).
Kintscher, U. & Law, R. E. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab. 288, E287–E291 (2005).
Sugii, S. et al. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl Acad. Sci. USA 106, 22504–22509 (2009).
Abdelmalek, M. F. et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology doi:10.1002/hep.23535.
Kechagias, S. et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 57, 649–654 (2008).
Tetri, L. H., Basaranoglu, M., Brunt, E. M., Yerian, L. M. & Neuschwander-Tetri, B. A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G987–G995 (2008).
Collison, K. S. et al. Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease. J. Lipid Res. 50, 1521–1537 (2009).
Neuschwander-Tetri, B. A. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr. Gastroenterol. Rep. 12, 49–56 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Neuschwander-Tetri, B. Thiazolidinediones for NASH—one pill doesn't fix everything. Nat Rev Gastroenterol Hepatol 7, 243–244 (2010). https://doi.org/10.1038/nrgastro.2010.50
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.50
